Polygenic Score (PGS) ID: PGS000822

Predicted Trait
Reported Trait Urinary albumin to creatinine ratio
Mapped Trait(s) urinary albumin to creatinine ratio (EFO_0007778)
Released in PGS Catalog: July 29, 2021
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name GRS_UACR
Development Method
Name Genome-wide significant variants
Parameters P < 5e-8
Variants
Original Genome Build GRCh37
Number of Variants 59
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000206
Citation (link to publication) Teumer A et al. Nat Commun (2019)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 97%
African: 1.2%
East Asian: 1.1%
South Asian: 0.4%
Hispanic or Latin American: 0.3%
564,257 individuals (100%)
PGS Evaluation
European: 87.5%
African: 12.5%
8 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST008790
Europe PMC: 31511532
 547,361 individuals European 38 cohorts
  • AA-DHS
  • ,ADVANCE
  • ,AGES
  • ,AMISH
  • ,ARIC
  • ,BioVU
  • ,CHRIS
  • ,CHS
  • ,DIACORE
  • ,ESTHER
  • ,FHS
  • ,FINCAVAS
  • ,GCKD
  • ,Generation_R
  • ,JHS
  • ,KORA
  • ,LIFE-Adult
  • ,LIFE-Child
  • ,LifeLines
  • ,Living-Biobank
  • ,MESA
  • ,MICROS
  • ,MyCode
  • ,NEO
  • ,PIVUS
  • ,POPGEN
  • ,PREVEND
  • ,RS
  • ,SCES
  • ,SHIP
  • ,SIMES
  • ,SINDI
  • ,SKIPOGH
  • ,SORBS
  • ,SP2
  • ,UKB
  • ,ULSAM
  • ,deCODE
GWAS Catalog: GCST008790
Europe PMC: 31511532
 6,795 individuals African American or Afro-Caribbean 38 cohorts
  • AA-DHS
  • ,ADVANCE
  • ,AGES
  • ,AMISH
  • ,ARIC
  • ,BioVU
  • ,CHRIS
  • ,CHS
  • ,DIACORE
  • ,ESTHER
  • ,FHS
  • ,FINCAVAS
  • ,GCKD
  • ,Generation_R
  • ,JHS
  • ,KORA
  • ,LIFE-Adult
  • ,LIFE-Child
  • ,LifeLines
  • ,Living-Biobank
  • ,MESA
  • ,MICROS
  • ,MyCode
  • ,NEO
  • ,PIVUS
  • ,POPGEN
  • ,PREVEND
  • ,RS
  • ,SCES
  • ,SHIP
  • ,SIMES
  • ,SINDI
  • ,SKIPOGH
  • ,SORBS
  • ,SP2
  • ,UKB
  • ,ULSAM
  • ,deCODE
GWAS Catalog: GCST008790
Europe PMC: 31511532
 6,324 individuals East Asian 38 cohorts
  • AA-DHS
  • ,ADVANCE
  • ,AGES
  • ,AMISH
  • ,ARIC
  • ,BioVU
  • ,CHRIS
  • ,CHS
  • ,DIACORE
  • ,ESTHER
  • ,FHS
  • ,FINCAVAS
  • ,GCKD
  • ,Generation_R
  • ,JHS
  • ,KORA
  • ,LIFE-Adult
  • ,LIFE-Child
  • ,LifeLines
  • ,Living-Biobank
  • ,MESA
  • ,MICROS
  • ,MyCode
  • ,NEO
  • ,PIVUS
  • ,POPGEN
  • ,PREVEND
  • ,RS
  • ,SCES
  • ,SHIP
  • ,SIMES
  • ,SINDI
  • ,SKIPOGH
  • ,SORBS
  • ,SP2
  • ,UKB
  • ,ULSAM
  • ,deCODE
GWAS Catalog: GCST008790
Europe PMC: 31511532
 2,335 individuals South Asian 38 cohorts
  • AA-DHS
  • ,ADVANCE
  • ,AGES
  • ,AMISH
  • ,ARIC
  • ,BioVU
  • ,CHRIS
  • ,CHS
  • ,DIACORE
  • ,ESTHER
  • ,FHS
  • ,FINCAVAS
  • ,GCKD
  • ,Generation_R
  • ,JHS
  • ,KORA
  • ,LIFE-Adult
  • ,LIFE-Child
  • ,LifeLines
  • ,Living-Biobank
  • ,MESA
  • ,MICROS
  • ,MyCode
  • ,NEO
  • ,PIVUS
  • ,POPGEN
  • ,PREVEND
  • ,RS
  • ,SCES
  • ,SHIP
  • ,SIMES
  • ,SINDI
  • ,SKIPOGH
  • ,SORBS
  • ,SP2
  • ,UKB
  • ,ULSAM
  • ,deCODE
GWAS Catalog: GCST008790
Europe PMC: 31511532
 1,442 individuals Hispanic or Latin American 38 cohorts
  • AA-DHS
  • ,ADVANCE
  • ,AGES
  • ,AMISH
  • ,ARIC
  • ,BioVU
  • ,CHRIS
  • ,CHS
  • ,DIACORE
  • ,ESTHER
  • ,FHS
  • ,FINCAVAS
  • ,GCKD
  • ,Generation_R
  • ,JHS
  • ,KORA
  • ,LIFE-Adult
  • ,LIFE-Child
  • ,LifeLines
  • ,Living-Biobank
  • ,MESA
  • ,MICROS
  • ,MyCode
  • ,NEO
  • ,PIVUS
  • ,POPGEN
  • ,PREVEND
  • ,RS
  • ,SCES
  • ,SHIP
  • ,SIMES
  • ,SINDI
  • ,SKIPOGH
  • ,SORBS
  • ,SP2
  • ,UKB
  • ,ULSAM
  • ,deCODE

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM002203 PSS001079|
European Ancestry|
232,751 individuals
 PGP000206 |
Teumer A et al. Nat Commun (2019)
 Reported Trait: Microalbuminuria — — Odds Ratio (OR, top 25% vs bottom 25%): 1.69 [1.64, 1.75]
Beta (top 25% vs bottom 25%): 0.527 (0.018)		 — —
PPM002204 PSS001074|
European Ancestry|
182,870 individuals
 PGP000206 |
Teumer A et al. Nat Commun (2019)
 Reported Trait: Disorders of lipid metabolism OR: 1.58
β: 0.46 (0.07)		 — — PCs(1-10), sex —
PPM002206 PSS001074|
European Ancestry|
182,870 individuals
 PGP000206 |
Teumer A et al. Nat Commun (2019)
 Reported Trait: Mixed hyperlipidemia OR: 1.69
β: 0.53 (0.11)		 — — PCs(1-10), sex —
PPM002207 PSS001078|
European Ancestry|
121,142 individuals
 PGP000206 |
Teumer A et al. Nat Commun (2019)
 Reported Trait: Fuchs' dystrophy OR: 6.68 [3.06, 14.59]
β: 1.9 (0.4)		 — — PCs(1-10), sex —
PPM002208 PSS001073|
European Ancestry|
182,884 individuals
 PGP000206 |
Teumer A et al. Nat Commun (2019)
 Reported Trait: Hypertension OR: 1.38
β: 0.32 (0.07)		 — — PCs(1-10), sex —
PPM002209 PSS001073|
European Ancestry|
182,884 individuals
 PGP000206 |
Teumer A et al. Nat Commun (2019)
 Reported Trait: Essential hypertension OR: 1.37
β: 0.32 (0.07)		 — — PCs(1-10), sex —
PPM002210 PSS001077|
European Ancestry|
186,343 individuals
 PGP000206 |
Teumer A et al. Nat Commun (2019)
 Reported Trait: Proteinuria OR: 2.7 [1.76, 4.14]
β: 0.99 (0.22)		 — — PCs(1-10), sex —
PPM002205 PSS001074|
European Ancestry|
182,870 individuals
 PGP000206 |
Teumer A et al. Nat Commun (2019)
 Reported Trait: Hyperlipidemia OR: 1.58
β: 0.46 (0.07)		 — — PCs(1-10), sex —
PPM002212 PSS001075|
European Ancestry|
188,088 individuals
 PGP000206 |
Teumer A et al. Nat Commun (2019)
 Reported Trait: Gout and other crystal arthropathies OR: 1.58
β: 0.46 (0.1)		 — — PCs(1-10), sex —
PPM002213 PSS001076|
European Ancestry|
73,407 individuals
 PGP000206 |
Teumer A et al. Nat Commun (2019)
 Reported Trait: Hypercholesterolemia OR: 1.47
β: 0.39 (0.09)		 — — PCs(1-10), sex —
PPM002211 PSS001075|
European Ancestry|
188,088 individuals
 PGP000206 |
Teumer A et al. Nat Commun (2019)
 Reported Trait: Gout OR: 1.6
β: 0.47 (0.1)		 — — PCs(1-10), sex —
PPM021122 PSS011530|
African Ancestry|
288 individuals
 PGP000613 |
Rashkin SR et al. Br J Haematol (2021)
|Ext.		 Reported Trait: Time to albuminuria in children with sickle cell anaemia HR: 1.49
β: 0.4 (0.17)		 — — Sex, hydroxycarbamide duration, chronic transfusion duration, first 5 PCs Only 45 of 59 SNPs were used for score calculation based on MAF > 0.05
PPM021123 PSS011530|
African Ancestry|
288 individuals
 PGP000613 |
Rashkin SR et al. Br J Haematol (2021)
|Ext.		 Reported Trait: Time to albuminuria in children with sickle cell anaemia HR: 1.46
β: 0.38 (0.16)		 — — Sex, hydroxycarbamide duration, chronic transfusion duration, first 5 PCs, known sickle cell anaemia chronic kidney disease risk factors (α-thalessemia allele -α deletion, APOL1, BCL11A SNP rs1427407, HMOX1 SNP rs743811) Only 45 of 59 SNPs were used for score calculation based on MAF > 0.05

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS001073 Cases were individuals with hypertension. Of the 136,370 cases, 136,053 had essential hypertension. —
[
  • 136,370 cases
  • , 46,514 controls
]
 — European — MVP —
PSS001074 Cases were individuals with disorders of lipid metabolism. Of the 141,461 cases, 141,331 had hyperlipidemia and 19,150 had mixed hyperlipidemia. —
[
  • 141,461 cases
  • , 41,409 controls
]
 — European — MVP —
PSS001075 Cases were individuals with gout and other crystal arthropathies. Of the 15,484 cases, 15,011 specifically, had gout. —
[
  • 15,484 cases
  • , 172,524 controls
]
 — European — MVP —
PSS001076 Cases were individuals with hypercholesterolemia. —
[
  • 31,998 cases
  • , 41,409 controls
]
 — European — MVP —
PSS001077 Cases were individuals with proteinuria. —
[
  • 3,122 cases
  • , 183,221 controls
]
 — European — MVP —
PSS001078 Cases were individuals with Fuchs' disease. —
[
  • 874 cases
  • , 120,268 controls
]
 — European — MVP —
PSS001079 Cases were individuals with microalbuminuria (MA). MA was defined by a urinary albumin to creatinine ratio (UACR) > 30 mg/g. —
[
  • 30,014 cases
  • , 202,737 controls
]
 — European — UKB Possible sample overlap (up to 41%) between this dataset and the dataset used to source GRS_UACR.
PSS011530 Albuminuria was defined by a urine albumin to creatinine ratio (UCAR) of > 30mg/g. Time to albuminuria was defined as the age at first instance of UACR > 30mg/g during follow-up. Mean = 3.54 years
Sd = 3.02 years
[
  • 60 cases
  • , 228 controls
]
,
52.08 % Male samples
 Mean = 8.1 years
Sd = 3.7 years		 African American or Afro-Caribbean — SCCRIP —